With a short percentage of shares outstanding of 0.51%, Novo Nordisk A/S (NYSE:NVO) is among the 7 Best Longevity and Anti-Aging Stocks to Buy
On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares
Earlier, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved the Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity. The approval makes the therapy the first oral GLP-1 receptor agonist authorized for weight management in adults living with obesity or overweight who also have at least one weight-related medical condition. The decision was supported by data from the Phase 3 OASIS 4 clinical trial and expands Novo Nordisk’s obesity treatment portfolio by offering patients a non-injectable alternative to existing therapies.
Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in chronic conditions like diabetes and obesity. It is primarily known for developing lifesaving GLP-1 therapies like Ozempic and Wegovy, but it also targets the underlying metabolic and cardiovascular diseases that reduce lifespan
While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock
READ NEXT:10 Most Overvalued Quantum Computing Stocks According to Short Sellers and7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue
Disclosure: None. Follow Insider Monkey on Google News
